US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Glaxo’s growth problem
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
Why ipatasertib is not the Akt Astra wants to follow
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.
Novo takes the plunge in Alzheimer’s
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
What the coming year might hold for biopharma
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
